+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Actemra"

Interleukin Inhibitors Market Report 2025 - Product Thumbnail Image

Interleukin Inhibitors Market Report 2025

  • Report
  • April 2025
  • 250 Pages
  • Global
From
Arthritis Monoclonal Antibodies Market Report 2025 - Product Thumbnail Image

Arthritis Monoclonal Antibodies Market Report 2025

  • Report
  • April 2025
  • 250 Pages
  • Global
From
InterLeukin6 IL6 Inhibitor Market Report 2025 - Product Thumbnail Image

InterLeukin6 IL6 Inhibitor Market Report 2025

  • Report
  • April 2025
  • 200 Pages
  • Global
From
Arthritic Therapeutic Market Report 2025 - Product Thumbnail Image

Arthritic Therapeutic Market Report 2025

  • Report
  • April 2025
  • 200 Pages
  • Global
From
InterLeukin6 IL6 Inhibitor Market 2024 - Product Thumbnail Image

InterLeukin6 IL6 Inhibitor Market 2024

  • Report
  • December 2024
  • 175 Pages
  • Global
From
From
From
From
From
From
From
From
Still's Disease - Pipeline Insight, 2024 - Product Thumbnail Image

Still's Disease - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Polymyositis - Pipeline Insight, 2024 - Product Thumbnail Image

Polymyositis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
ACTEMRA Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

ACTEMRA Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • January 2023
  • 30 Pages
  • Global
From
From
Loading Indicator

Actemra (tocilizumab) is a monoclonal antibody used to treat immune disorders, such as rheumatoid arthritis, giant cell arteritis, and systemic juvenile idiopathic arthritis. It works by blocking the action of interleukin-6, a protein that plays a role in inflammation. Actemra is approved for use in adults and children, and is administered intravenously or subcutaneously. The Actemra market is a subset of the larger immune disorders drugs market. It is a growing market, driven by the increasing prevalence of autoimmune diseases and the need for effective treatments. Actemra is a key player in this market, as it is the only approved treatment for certain conditions, such as giant cell arteritis. Companies in the Actemra market include Roche, which manufactures and markets the drug, as well as other pharmaceutical companies that develop and market treatments for immune disorders. Show Less Read more